The latest market report published by Credence Research, Inc. “Prostate Cancer Treatment Market By Treatment (Biological Therapy, Chemotherapy )- Growth, Future Prospects, Competitive Analysis and Pipeline Analysis, 2017 - 2025,” the prostate cancer treatment market was valued at US$ 7,768.6 Mn in 2016, and is expected to reach US$ 16,757.2 Mn by 2025 expanding at a CAGR of 7.80 % from 2017 to 2025.
Browse the full report at https://www.credenceresearch.com/report/prostate-cancer-treatment-market
Market Insights
The key risk factors for prostate cancer development is being old age, genetic, obesity and race. Around 99% of the cases for prostate cancer is most commonly seen after the age of 50 years. The currently available treatment are biological therapy and chemotherapy. Biological therapy are considered as the largest segment of prostate cancer treatment market as it is the preferred first line of treatment. Chemotherapy is an option to the patients who are resistant to the Biological therapy. The key factors assisting the growth of prostate cancer treatment market are growing prevalence of prostate cancer coupled with growing public awareness, rising healthcare expenditure in the developed and developing regions and developing technology of pharmaceutical companies leading to more target specific drugs with lesser side effects and strong emerging pipeline. On the other hand, insufficient funding in developing and under developed countries and high cost involved in the treatment of the disease are hindering the market growth of prostate cancer treatment.
Pipeline Analysis
Pipeline of prostate cancer treatment market is dense and comprises combination of biological drugs and chemotherapy drugs. However, the no. of biological therapy molecules is more in the phase III of clinical trials compared to chemotherapy. We have estimated sales of very specific molecules based on the type (biological or chemical), disease prevalence, sponsor, depicted peak sales by leading market experts and other factors.
Key Market Movements:
- Rising prevalence of prostate cancer in developed and developing countries
- Aging population, in developed countries is expected to boost the market
- Government and non-government initiatives to fight prostate cancer and supporting reimbursement policies
- Rising public awareness with early disease diagnosis and strong emerging pipeline is expected to boost the Prostate cancer treatment market
Download Free PDF Sample Request: https://www.credenceresearch.com/sample-request/58402
Table of Content
Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions
Chapter 2 Executive Summary
2.1 Global Prostate Cancer Treatment Market Portraiture
2.2 Global Prostate Cancer Treatment Market, by Type of Treatment, 2016 (US$ Mn)
2.3 Global Prostate Cancer Treatment Market Share, by Geography, 2016 (Value %)
2.1 Global Prostate Cancer Treatment Market Portraiture
2.2 Global Prostate Cancer Treatment Market, by Type of Treatment, 2016 (US$ Mn)
2.3 Global Prostate Cancer Treatment Market Share, by Geography, 2016 (Value %)
Chapter 3 Prostate Cancer Treatment Market Analysis
3.1 Global Prostate Cancer Treatment Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.1.1 Growing Prevalence of Prostate Cancer
3.2.1.2 Rise in aging population and public awareness of Prostate cancer
3.2.2 Challenges
3.2.2.1 Ambiguous Reimbursement Policies causing decrease in healthcare expenditure
3.2.3 Opportunities
3.2.3.1 Developing R&D technology leading to more target specific drugs and strong emerging pipeline
3.3 Attractive Investment Proposition
3.4 Competitive Landscape of Key Players in Prostate Cancer Treatment Market
3.1 Global Prostate Cancer Treatment Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.1.1 Growing Prevalence of Prostate Cancer
3.2.1.2 Rise in aging population and public awareness of Prostate cancer
3.2.2 Challenges
3.2.2.1 Ambiguous Reimbursement Policies causing decrease in healthcare expenditure
3.2.3 Opportunities
3.2.3.1 Developing R&D technology leading to more target specific drugs and strong emerging pipeline
3.3 Attractive Investment Proposition
3.4 Competitive Landscape of Key Players in Prostate Cancer Treatment Market
Chapter 4 Global Prostate Cancer Treatment Market Analysis, by Treatment
4.1 Introduction
4.2 Biological Therapy
4.2.1 Enzalutamid
4.2.2 Abiraterone
4.2.3 Leuprolide
4.2.4 Goserelin
4.2.5 Triptorelin
4.2.6 Histrelin
4.2.7 Degarelix
4.2.8 Sipuleucel-T
4.3 Chemotherapy
4.3.1 Mitotic inhibitors e.g. Docetaxel, Cabazitaxel
4.3.2 Topoisomerase inhibitors e.g. Mitoxantrone
4.3.3 Alkylating antineoplastic agent e.g. Estramustine
4.1 Introduction
4.2 Biological Therapy
4.2.1 Enzalutamid
4.2.2 Abiraterone
4.2.3 Leuprolide
4.2.4 Goserelin
4.2.5 Triptorelin
4.2.6 Histrelin
4.2.7 Degarelix
4.2.8 Sipuleucel-T
4.3 Chemotherapy
4.3.1 Mitotic inhibitors e.g. Docetaxel, Cabazitaxel
4.3.2 Topoisomerase inhibitors e.g. Mitoxantrone
4.3.3 Alkylating antineoplastic agent e.g. Estramustine
Chapter 5 Global Prostate Cancer Treatment Market, By Geography
5.1 Preface
5.2 North America (U.S. & Canada)
5.3 Europe (U.K., Germany & Rest of Europe)
5.4 Asia Pacific (China, Japan and Rest of APAC)
5.5 Latin America (Brazil, Mexico and Rest of Latin America)
5.6 Middle East and Africa (United Arab Emirates, Saudi Arabia and Rest of Middle East and Africa)
5.1 Preface
5.2 North America (U.S. & Canada)
5.3 Europe (U.K., Germany & Rest of Europe)
5.4 Asia Pacific (China, Japan and Rest of APAC)
5.5 Latin America (Brazil, Mexico and Rest of Latin America)
5.6 Middle East and Africa (United Arab Emirates, Saudi Arabia and Rest of Middle East and Africa)
Chapter 6 Company Profiles
6.1 Tolmar Inc.
6.2 Astellas Pharma, Inc.
6.3 AstraZeneca Plc
6.4 Ferring Pharmaceuticals
6.5 Johnson & Johnson
6.6 Abbott Laboratories
6.7 Sanofi
6.8 Ipsen
6.9 Novartis
6.10 Bayer Healthcare Pharmaceuticals, Inc
6.1 Tolmar Inc.
6.2 Astellas Pharma, Inc.
6.3 AstraZeneca Plc
6.4 Ferring Pharmaceuticals
6.5 Johnson & Johnson
6.6 Abbott Laboratories
6.7 Sanofi
6.8 Ipsen
6.9 Novartis
6.10 Bayer Healthcare Pharmaceuticals, Inc
Have A Relaxing Weekend!
ReplyDelete